AzurRx Provides Update on MS1819 Phase II Trial Initial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
39
AzurRx Provides Update on MS1819 Phase II Trial

Initial patient experience shows no safety issues

MS1819 appears active, as demonstrated by CFA increases >20% at various dosing levels

BROOKLYN, N.Y., April 11, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today is providing an update on the ongoing open-label Phase IIa trial of lead candidate MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis (CP). The trial is being conducted in partnership with Mayoly Spindler, a European pharmaceutical company.   

Early results indicate that MS1819 exhibits a favorable safety profile, with no moderate or severe adverse events having been reported to date.  Additionally, no patients have dropped out of the study once they have qualified to take the active drug.  Regarding efficacy, results to date indicate that MS1819 is active, as measured by coefficient of fat absorption (CFA), which is the parameter being measured for the primary efficacy endpoint.  There was a favorable dose response of greater than 20% improvement in CFA seen in all patients at either the second or third of the four escalating dosage levels of MS 1819. 

These early efficacy and favorable safety results from the ongoing Phase IIa trial confirm data from the previously performed Phase Ib trial of MS1819. The company expects study completion in the third-quarter of 2017.

Thijs Spoor, CEO of AzurRx BioPharma, said, “We are extremely encouraged by these early Phase IIa MS1819 data, observing a clear dose-response pattern with clean safety characteristics.  We continue to expect MS1819 to show a superior efficacy, safety, and dosing profile relative to the currently marketed pancreatic enzyme replacement therapies (PERT).” 

Dr. Richard Stubbs, Managing Director of P3 Research, in Wellington, New Zealand and Clinical Investigator said, “Our patient satisfaction is very high in this study as underscored by an expressed interest in joining in further studies of MS1819. Physician response has also been favorable.  We are delighted to play a key role in developing products that have significant potential to change patient care.”

MS1819 Phase IIa Trial

AzurRx is currently conducting a Phase IIa trial of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatic pancreatitis (CP).  The study is being performed at four sites in Australia and New Zealand with a target enrollment of 12-15 patients. In addition to assessing safety, AzurRx is evaluating four escalating dose increments of MS1819, with the aim of elucidating the optimal treatment dose to be taken into subsequent registration trials in EPI patients with chronic pancreatitis (CP) and cystic fibrosis (CF).  The primary efficacy endpoint is the change in CFA from baseline and measured at the end of the open label treatment part of the trial (Phase C) on standardized high-fat meals and stool collection for 3 days.  AzurRx continues to expect completion of this Phase IIa trial in 3Q17.   Information about the trial can be found on the following website:  http://www.anzctr.org.au/TrialSearch.aspx?sea...Basic=True .

About MS1819, a Recombinant Lipase

MS1819, a recombinant lipase derived from the yeast Yarrowia Lipolytica, is in development for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis (CP) and cystic fibrosis (CF).  Early Phase Ib data in EPI patients treated with MS1819 showed a favorable safety profile and encouraging preliminary signals of efficacy.

There are approximately 100,000 patients in the U.S. with EPI caused by CP according to the National Pancreas Foundation and more than 30,000 patients with EPI caused by CF according to the Cystic Fibrosis Foundation. Patients are currently treated with porcine pancreatic enzyme replacement pills. The U.S. market for such EPI porcine replacement therapy pills in 2016 was estimated to be approximately $950 million in the U.S. and $1.5 billion globally according to IMS data and Wall Street estimates.

AzurRx and Laboratoires Mayoly Spindler are party to a joint Research and development agreement and are collaborating on the development of a yeast derived recombinant lipase for the oral treatment of Exocrine pancreatic insufficiency (EPI).  Under terms of their partnership agreement, AzurRx has marketing rights for the recombinant Lipase in various geographies, including exclusive rights for North America.

About Laboratoires Mayoly Spindler, SAS Mayoly Spindler is a French, independent, family-owned pharmaceutical company, active in research, development, manufacturing, registration and marketing of pharmaceuticals and dermo-cosmetics in more than 70 countries. The company aims to become a global reference in gastroenterology and dermocosmetics. Mayoly Spindler is headquartered in the Paris area of France, and employs 750 people worldwide. Mayoly Spindler website address:  www.mayoly-spindler.com

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigations Reform Act of 1995. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the development and testing of our drug candidates, the regulatory approval process, our ability to secure additional financing, the protection of our patent and intellectual property, the success of strategic agreements and relationships, and the potential commercialization of any product we may successfully develop.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. For a discussion of such risks and uncertainties, see “Risk Factors” in AzurRx’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its other reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

CONTACT: For more Information: AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 217 Brooklyn, NY 11226 Phone: 646.699.7855 http://www.azurrx.com  info@azurrx.com Laboratories Mayoly Spindler 6 Avenue de l'Europe B.P. 51 - 78401 CHATOU Cedex - France Phone: +33(0)1 34 80 57 00 Fax: + 33(0)1 34 80 41 11 http://www.mayoly-spindler.com  contact@mayoly.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 305

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 43

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 279

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 85

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 19

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 294

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 164

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Cryptocurrency Through Sustainable Mining Solutions

Updated Category News Views 132

Ripple and Dogecoin Capture Market Attention Recently, Ripple, known by its trading symbol XRP, regained significant visibility in the cryptocurrency market following a major legal victory against a regulatory body. This resurgence has reignited interest among investors and enthusiasts alike. Meanwhile, Dogecoin has been experiencing a renaissance, driven by the ambitious...

Continue Reading
General Dynamics Sees Growth in Q2 Earnings and Revenue

Updated Category News Views 147

General Dynamics Q2 Financial Highlights General Dynamics reported remarkable financial results for the second quarter of 2025, showcasing a revenue of $13 billion, which marks an 8.9% increase compared to the same quarter last year. The company achieved operating earnings of $1.3 billion, translating to a diluted earnings per share (EPS) of $3.74, reflecting a 14.7%...

Continue Reading
FIU Shines as a Top Public University in New Ranking

Updated Category News Views 77

FIU Ranks High in TIME's New College List Alright, listen up. The latest college buzz isn't just noise—Florida International University (FIU) is sitting pretty at No. 23 among public universities in TIME's first crack at America's Best Colleges for the 2026-2027 term. They're also punching in at No. 62 overall out of 500 schools. For a university that's been...

Continue Reading
Recent Net Asset Value Disclosure for Hargreave Hale AIM VCT

Updated Category News Views 174

Understanding the Latest Net Asset Value Announcement The Hargreave Hale AIM VCT PLC has recently made an important announcement regarding its Net Asset Value (NAV). This provides valuable insights for investors and stakeholders looking to evaluate the fund's performance. It is crucial for those following this investment vehicle to stay informed about NAV updates, as...

Continue Reading
Orvana Minerals Corp. Reports Financial Results for Q1 FY2026

Updated Category News Views 191

Orvana Minerals Corp. Financial Performance Overview TSX:ORV Orvana Minerals Corp. (TSX: ORV) has recently disclosed its financial statements for the first quarter of the fiscal year 2026 through its subsidiary, Empresa Minera Paitití, S.A. (EMIPA). These unaudited results are now available for viewing on the Bolivian stock market. The disclosure marks an important...

Continue Reading